Patents by Inventor Nisha Rajagopal

Nisha Rajagopal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9
    Publication number: 20230210852
    Abstract: The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with a CDK7 inhibitor (e.g., THZ1, THZ2, SY-1365, YKL-5-124, ICEC0942, LY3405105, LDC4297, BS-181, alvocidib, seliciclib, SNS-32 or a pharmaceutically acceptable salt thereof, or a compound of structural Formula (I), (Ia), a species thereof, or a pharmaceutically acceptable salt thereof), either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy). Patients are identified based on one or more features (e.g., gene copy number or expression level) of certain biomarkers (e.g., KRAS and/or the chromosomal band 9q34).
    Type: Application
    Filed: May 28, 2021
    Publication date: July 6, 2023
    Inventors: John Graeme Hodgson, Liv Helena Johannessen, Nisha Rajagopal, Anthony D'ppolito
  • High-throughput CRISPR-based library screening
    Patent number: 11306308
    Abstract: Provided herein is an improved method for performing CRISPR/Cas based screening that is not dependent on viral cloning methods.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 19, 2022
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: David K. Gifford, Nisha Rajagopal, Richard Irving Sherwood
  • COMPOSITIONS AND METHODS FOR TREATING CANCERS WITH COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
    Publication number: 20200113902
    Abstract: The present invention relates to methods of identifying subjects suffering from various types of cancer who are more likely to respond to treatment with a covalent CDK7 inhibitor, such as N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide (Compound 1), either alone or in combination with other classes of anti-cancer therapies based on the presence or absence of certain biomarkers. In addition, the present invention relates to combinations of Compound 1 and one or more other anti-cancer therapies, kits containing them, and the use of such combinations in treating subjects suffering from various types of cancers.
    Type: Application
    Filed: June 12, 2018
    Publication date: April 16, 2020
    Inventors: Nisha Rajagopal, Graeme Hodgson, Emmanuelle Di Tomaso, Liv Helena Johannessen, Shanhu Hu
  • HIGH-THROUGHPUT CRISPR-BASED LIBRARY SCREENING
    Publication number: 20180327740
    Abstract: Provided herein is an improved method for performing CRISPR/Cas based screening that is not dependent on viral cloning methods.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 15, 2018
    Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: David K. Gifford, Nisha Rajagopal, Richard Irving Sherwood